Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC

A Phase II randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic Non-small cell lung cancer patients.

Trial Details

NCT ID
NCT05277844
Phase
PHASE2
Sponsor
Tata Memorial Hospital
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Local Consolidative Radiation Therapy
  • TKI
Locations (sample)
  • Mumbai, Maharashtra, India|19.07283,72.88261

Key Eligibility Criteria

  • Patients with pathologically proven diagnosis of NSCLC
  • Patients with positive oncogene driver mutation (EGFR or ALK/ROS)
  • Patients who have received at least 2-4 months of TKI therapy without progression
  • Patients with 1-5 sites of metastatic disease not including the primary tumor and regional nodes (less than 3 metastatic lesions in one organ will …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →